Canaccord lowered the firm’s price target on Doximity (DOCS) to $50 from $71 and keeps a Hold rating on the shares. The firm said as expected, Doximity completed its FY’25 with a strong beat, maybe not to the degree as 3Q, but still nothing to sneeze at with revenue and adj-EBITDA upside of roughly 4% and roughly 10% versus their estimates.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity: Strong Performance Amidst Cautious Outlook Warrants Hold Rating
- Doximity’s Strong Q4 Performance Overshadowed by Cautious FY 2026 Outlook: Hold Rating Maintained
- Doximity Hold Rating: Strong Performance Overshadowed by Policy Uncertainties and Cautious Upsell Momentum
- Cautious Outlook for Doximity Amid Strong Financials and Macroeconomic Uncertainties
- Doximity’s Strong Financial Performance and Strategic Positioning Justify Buy Rating